A new prognostic score for AIDS-related lymphomas in the rituximab-era.

Abstract

While the International Prognostic Index is commonly used to predict outcomes in immunocompetent patients with aggressive B-cell non-Hodgkin lymphomas, HIV-infection is an important competing risk for death in patients with AIDS-related lymphomas. We investigated whether a newly created prognostic score (AIDS-related lymphoma International Prognostic Index) could better assess risk of death in patients with AIDS-related lymphomas. We randomly divided a dataset of 487 patients newly diagnosed with AIDS-related lymphomas and treated with rituximab-containing chemoimmunotherapy into a training (n=244) and validation (n=243) set. We examined the association of HIV-related and other known risk factors with overall survival in both sets independently. We defined a new score (AIDS-related lymphoma International Prognostic Index) by assigning weights to each significant predictor [age-adjusted International Prognostic Index, extranodal sites, HIV-score (composed of CD4 count, viral load, and prior history of AIDS)] with three risk categories similar to the age-adjusted International Prognostic Index (low, intermediate and high risk). We compared the prognostic value for overall survival between AIDS-related lymphoma International Prognostic Index and age-adjusted International Prognostic Index in the validation set and found that the AIDS-related lymphoma International Prognostic Index performed significantly better in predicting risk of death than the age-adjusted International Prognostic Index (P=0.004) and better discriminated risk of death between each risk category (P=0.015 vs. P=0.13). Twenty-eight percent of patients were defined as low risk by the ARL-IPI and had an estimated 5-year overall survival (OS) of 78% (52% intermediate risk, 5-year OS 60%; 20% high risk, 5-year OS 50%).

• Authors: Stefan K Barta, Xiaonan Xue, Dan Wang, Jeannette Y Lee, Lawrence D Kaplan, Josep-Maria Ribera, Albert Oriol, Michele Spina, Umberto Tirelli, Francois Boue, Wyndham H Wilson, Christoph Wyen, Kieron Dunleavy, Ariela Noy, Joseph A Sparano
• Journal: Haematologica (Haematologica) Vol. 99 Issue 11 Pg. 1731-7 (Nov 2014) ISSN: 1592-8721 [Electronic] Italy
• PMID: 25150257 (Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© Ferrata Storti Foundation.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• CD4 Lymphocyte Count
• Clinical Trials as Topic
• Female
• Humans
• Lymphoma, AIDS-Related (diagnosis, drug therapy, mortality)
• Male
• Middle Aged
• Prognosis
• Rituximab
• Treatment Outcome
• Viral Load